ACH Earnings Date: Nov 5, 2026 (Estimated) — Accendra Health, Inc.
NYSE · Healthcare · Medical Distribution
Updated
When is ACH's next earnings date?
Accendra Health, Inc. (ACH) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.05 on revenue of $618.3M.
How did ACH do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Accendra Health, Inc. posted EPS of -$0.19 versus the -$0.08 estimate, a miss of 90.0%. Revenue was $613.2M against a $628.7M estimate. The stock's 1-day post-earnings move was -50.0%.
How much does ACH stock move after earnings?
ACH beat EPS estimates in 5 of its last 8 reported quarters. Over the last 3 reports the stock moved an average of 21.3% (up or down) in the day after earnings.
About Accendra Health, Inc.
Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.08 | -0.19 | -90.00% | $613.2M | ❌ Miss | -50.00% | -66.04% | -60.71% |
| 2026-05-11 | Q1 2026 | -0.09 | -0.04 | +55.56% | $627.8M | ✅ Beat | +8.66% | -18.72% | -25.42% |
| 2026-02-19 | Q4 2025 | 0.22 | 0.21 | -4.55% | $709.0M | ❌ Miss | +5.24% | -2.42% | -20.97% |
| 2022-11-02 | 0.39 | 0.41 | — | $2.50B | ✅ Beat | — | — | — | |
| 2022-08-03 | 0.76 | 0.76 | — | $2.50B | ➖ Inline | — | — | — | |
| 2022-05-03 | 0.77 | 0.96 | — | $2.41B | ✅ Beat | — | — | — | |
| 2022-02-23 | 0.67 | 0.81 | — | $2.47B | ✅ Beat | — | — | — | |
| 2021-11-03 | 0.55 | 0.74 | — | $2.50B | ✅ Beat | — | — | — |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $318.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Diabetes Product | 62.5% | $198.8M | +4.1% | — | — | $191.1M | $201.4M |
| Product and Service, Other | 15.0% | $47.7M | -34.1% | — | — | $72.3M | $72.6M |
| Wound Care | 12.6% | $40.2M | -14.2% | — | — | $46.8M | $48.0M |
| Urology | 9.8% | $31.3M | +9.1% | — | — | $28.7M | $29.0M |
By region
Q1 FY25 · $2.63B total
| Segment | Share | Revenue | YoY | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 98.0% | $2.58B | +1.2% | $2.52B | $2.59B | $2.55B | $2.61B |
| Non-US | 2.0% | $51.3M | -17.3% | $72.8M | $67.9M | $62.1M | $62.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.